SXTCHealthcare · Drug Manufacturers - Specialty & Generic

SXTC Stock Forecast: China Sxt Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026

$2.56

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 11 of 100 as at 12 Sept 2026 — in the weakest quartile.

Market cap

$3.4M

Ticker Nerd rank

11 / 100

Median analyst target

—

Analysts covering

—

Ticker Nerd rank

SXTC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores China Sxt Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026

11 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Volatility

Quality

Accruals

Growth

Revisions

Momentum

Issuance

Value

Size (98): Smaller than most of the companies we track.

Value (4): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SXTC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SXTC, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SXTC appears on the weeks it earns a place.

Estimates

SXTC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

China Sxt Pharmaceuticals, Inc. (SXTC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 0.0×
Price / sales: 3.0×
Price / book: 0.0×
EV / EBITDA: 3.7×

Growth & margins

Revenue growth (YoY): −43.9%
Earnings growth (YoY): —
Gross margin: —
Operating margin: −153.3%
Net margin: 21.9%

Returns & dividend

Return on equity: −27.5%
Return on assets: −15.8%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

China Sxt Pharmaceuticals, Inc. (SXTC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

China Sxt Pharmaceuticals, Inc. has a market value of $3.4M and an enterprise value of −$26.2M.
Shares outstanding: 11,976.
Trailing P/E: 0.0×.
China Sxt Pharmaceuticals, Inc. employs 56 people.

market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

SXTC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic

Company	Market cap	TKN rank
SXTCChina Sxt Pharmaceuticals, Inc.	$3.4M	11
APUSApimeds Pharmaceuticals US, Inc.	$3.2M	9
SBFMSunshine Biopharma, Inc.	$4.1M	61
PRFXPRF Technologies Ltd.	$2.6M	4
BTAIBioXcel Therapeutics, Inc.	$2.3M	—
SHPHShuttle Pharmaceuticals Holdings, Inc.	$2.2M	16
YCBDcbdMD, Inc.	$5.4M	28

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own China Sxt Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SXTC news & analysis

China SXT Pharmaceuticals, Inc. Announces Share Consolidation

GlobeNewsWire · 5 Aug 2026neutral

China SXT Pharmaceuticals, Inc. announced a 1-for-80 share consolidation of its Class A and Class B ordinary shares, effective August 10, 2026, with post-consolidation trading beginning that day.

Why it matters — A share consolidation reduces the number of outstanding shares and typically increases the per-share price, which can affect the stock's trading characteristics and compliance with exchange listing requirements.

Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)

GlobeNewsWire · 24 July 2026positive

Univest Securities, LLC announced the closing of a registered direct offering worth approximately $9 million for its client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC), described as a China-based innovative pharmaceutical company focused on traditional Chinese medicine pieces.

Why it matters — The completion of this $9 million offering indicates SXTC has secured additional capital through a registered direct placement, which may impact the company's financial position.

FAQ

Frequently asked questions about SXTC stock

How does Ticker Nerd's model rank SXTC?

As at 12 Sept 2026, China Sxt Pharmaceuticals, Inc. ranks 11 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).

What is the SXTC stock forecast for 2030?

No analyst covering China Sxt Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SXTC are extrapolating price history, which says nothing about the business.

What does China Sxt Pharmaceuticals, Inc. do?

China SXT Pharmaceuticals, Inc. is a pharmaceutical company focused on the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces.

What is the latest news on SXTC?

The most recent item we track (GlobeNewsWire, 5 Aug 2026): "China SXT Pharmaceuticals, Inc. Announces Share Consolidation". China SXT Pharmaceuticals, Inc. announced a 1-for-80 share consolidation of its Class A and Class B ordinary shares, effective August 10, 2026, with post-consolidation trading beginning that day.

Company

About China Sxt Pharmaceuticals, Inc.

China SXT Pharmaceuticals, Inc. is a pharmaceutical company focused on the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces. Its product lineup includes directly-oral, after-soaking-oral, fine, and regular TCMP formats, which are distributed under brands such as Suxuantang, Hui Chun Tang, and Tong Ren Tang. The company serves a range of customers in China, including hospitals, chain pharmacies, pharmaceutical distributors, and commercial pharmaceutical companies, positioning it within the domestic traditional medicine supply chain. Based in Taizhou, Jiangsu, China, China SXT Pharmaceuticals, Inc. operates in a specialized segment of the healthcare market centered on traditional Chinese medicine products.

CEO Mr. Feng Zhou · 56 employees · China · https://www.sxtchina.com